These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 9822546

  • 1. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
    Beall HD, Winski S, Swann E, Hudnott AR, Cotterill AS, O'Sullivan N, Green SJ, Bien R, Siegel D, Ross D, Moody CJ.
    J Med Chem; 1998 Nov 19; 41(24):4755-66. PubMed ID: 9822546
    [Abstract] [Full Text] [Related]

  • 2. Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1).
    Fryatt T, Pettersson HI, Gardipee WT, Bray KC, Green SJ, Slawin AM, Beall HD, Moody CJ.
    Bioorg Med Chem; 2004 Apr 01; 12(7):1667-87. PubMed ID: 15028260
    [Abstract] [Full Text] [Related]

  • 3. Nicotinamide adenine dinucleotide (phosphate): quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: quinone cytotoxicity and selectivity in human lung and breast cancer cell lines.
    Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D.
    Mol Pharmacol; 1995 Sep 01; 48(3):499-504. PubMed ID: 7565631
    [Abstract] [Full Text] [Related]

  • 4. Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.
    Newsome JJ, Swann E, Hassani M, Bray KC, Slawin AM, Beall HD, Moody CJ.
    Org Biomol Chem; 2007 May 21; 5(10):1629-40. PubMed ID: 17571194
    [Abstract] [Full Text] [Related]

  • 5. Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2.
    Swann E, Barraja P, Oberlander AM, Gardipee WT, Hudnott AR, Beall HD, Moody CJ.
    J Med Chem; 2001 Sep 27; 44(20):3311-9. PubMed ID: 11563930
    [Abstract] [Full Text] [Related]

  • 6. Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1.
    Beall HD, Hudnott AR, Winski S, Siegel D, Swann E, Ross D, Moody CJ.
    Bioorg Med Chem Lett; 1998 Mar 03; 8(5):545-8. PubMed ID: 9871615
    [Abstract] [Full Text] [Related]

  • 7. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J, Oleschuk CJ, Guziec F, Guziec L, Fiterman DJ, Monterrosa C, Begleiter A.
    Cancer Chemother Pharmacol; 2002 Feb 03; 49(2):101-10. PubMed ID: 11862423
    [Abstract] [Full Text] [Related]

  • 8. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
    Winski SL, Hargreaves RH, Butler J, Ross D.
    Clin Cancer Res; 1998 Dec 03; 4(12):3083-8. PubMed ID: 9865924
    [Abstract] [Full Text] [Related]

  • 9. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
    Colucci MA, Moody CJ, Couch GD.
    Org Biomol Chem; 2008 Feb 21; 6(4):637-56. PubMed ID: 18264564
    [Abstract] [Full Text] [Related]

  • 10. Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1.
    Hassani M, Cai W, Holley DC, Lineswala JP, Maharjan BR, Ebrahimian GR, Seradj H, Stocksdale MG, Mohammadi F, Marvin CC, Gerdes JM, Beall HD, Behforouz M.
    J Med Chem; 2005 Dec 01; 48(24):7733-49. PubMed ID: 16302813
    [Abstract] [Full Text] [Related]

  • 11. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
    Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, Ross D.
    Biochemistry; 2007 May 22; 46(20):5941-50. PubMed ID: 17455910
    [Abstract] [Full Text] [Related]

  • 12. Benzimidazole- and benzothiazole-quinones: excellent substrates for NAD(P)H:quinone oxidoreductase 1.
    Newsome JJ, Colucci MA, Hassani M, Beall HD, Moody CJ.
    Org Biomol Chem; 2007 Nov 21; 5(22):3665-73. PubMed ID: 17971996
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
    Siegel D, Franklin WA, Ross D.
    Clin Cancer Res; 1998 Sep 21; 4(9):2065-70. PubMed ID: 9748120
    [Abstract] [Full Text] [Related]

  • 14. Studies on quinones. Part 42: Synthesis of furylquinone and hydroquinones with antiproliferative activity against human tumor cell lines.
    Benites J, Valderrama JA, Rivera F, Rojo L, Campos N, Pedro M, José Nascimento MS.
    Bioorg Med Chem; 2008 Jan 15; 16(2):862-8. PubMed ID: 17964791
    [Abstract] [Full Text] [Related]

  • 15. Studies on quinones. Part 46. Synthesis and in vitro antitumor evaluation of aminopyrimidoisoquinolinequinones.
    Vásquez D, Rodríguez JA, Theoduloz C, Calderon PB, Valderrama JA.
    Eur J Med Chem; 2010 Nov 15; 45(11):5234-42. PubMed ID: 20828890
    [Abstract] [Full Text] [Related]

  • 16. COMPARE analysis of the toxicity of an iminoquinone derivative of the imidazo[5,4-f]benzimidazoles with NAD(P)H:quinone oxidoreductase 1 (NQO1) activity and computational docking of quinones as NQO1 substrates.
    Fagan V, Bonham S, Carty MP, Saenz-Méndez P, Eriksson LA, Aldabbagh F.
    Bioorg Med Chem; 2012 May 15; 20(10):3223-32. PubMed ID: 22522008
    [Abstract] [Full Text] [Related]

  • 17. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.
    Winski SL, Koutalos Y, Bentley DL, Ross D.
    Cancer Res; 2002 Mar 01; 62(5):1420-4. PubMed ID: 11888914
    [Abstract] [Full Text] [Related]

  • 18. 2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1).
    Bian J, Deng B, Xu L, Xu X, Wang N, Hu T, Yao Z, Du J, Yang L, Lei Y, Li X, Sun H, Zhang X, You Q.
    Eur J Med Chem; 2014 Jul 23; 82():56-67. PubMed ID: 24874653
    [Abstract] [Full Text] [Related]

  • 19. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
    Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1509-16. PubMed ID: 11377380
    [Abstract] [Full Text] [Related]

  • 20. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
    Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, Burke PJ.
    Cancer Res; 2000 Aug 01; 60(15):4179-86. PubMed ID: 10945627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.